PCM INC. news, videos and press releases
For more news please use our advanced search feature.
PCM INC. - More news...
PCM INC. - More news...
- PCM Trials Acquires Netherlands-Based Clinical Trial Service B.V., Becoming the Most Experienced Independent Provider of Mobile Visit Services with The Largest Geographic Coverage Area in Support of Decentralized Clinical Trials
- Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage
- HH Global to acquire PCM and PMS
- HH Global to acquire PCM and PMS
- Brandon H. LaVerne, Chief Financial Officer of $2.2 Billion Technology Solutions Provider, PCM, Inc., Joins Catasys as Chief Financial Officer
- SHAREHOLDER ALERT: WeissLaw LLP Investigates PCM, Inc. Acquisition
- PCM (PMCI) Alert: Johnson Fistel Investigates Proposed Sale of PCM, Inc.; Are Shareholders Getting a Fair Price?
- Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
- Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib (PCM-075) in Ongoing Phase 1b/2 AML Trial
- Trovagene Receives USAN Approval for "Onvansertib" as Nonproprietary Name for First-in-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075
- Trovagene Receives Positive Opinion for Orphan Drug Designation in the European Union for PCM-075, Trovagene's Investigational Cancer Drug
- Trovagene Announces Preliminary Clinical Data from First Dosing Cohort Demonstrating Durable Treatment Effect of PCM-075 in Combination with Cytarabine or Decitabine in Patients with Relapsed or Refractory AML
- Trovagene Announces the Start of Recruitment and Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® in Patients with mCRPC
- Trovagene Announces Completion of First Dosing Cohort of Patients Treated with PCM-075 in Combination with Decitabine in Ongoing Phase 1b/2 AML Trial
- Trovagene Announces Completion of First Dosing Cohort of Patients in Ongoing Phase 1b/2 Trial of PCM-075 in Acute Myeloid Leukemia
- Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine
- Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML)
- Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
- Trovagene Announces Activation of Two Additional Clinical Trial Sites to Conduct its Phase 1b/2 Study of PCM-075 in Patients with AML
- Trovagene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga® in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium
- Trovagene Announces Completion of Cycle-One Dosing in First Patient Enrolled in its Phase 1b/2 Clinical Trial of PCM-075 in Acute Myeloid Leukemia (AML)
- Trovagene Announces Initiation of UNITE Phase 2 Clinical Trial of PCM-075 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Trovagene Announces Activation of Second Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
- Trovagene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga® for Metastatic Castration-Resistant Prostate Cancer
- Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines to PCM-075 and Synergy with Zytiga® at San Antonio Breast Cancer Symposium (SABCS)
- Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075
- Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga® (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells
- FDA Grants Orphan Drug Designation to Trovagene's PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML)
- Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines
- Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy